Skip to main content

Table 1 Biodistribution of 3 H-FLT in mice bearing A431 tumors

From: Assessment of early changes in 3H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression

Tissue

3H-FLT uptake level ((%ID/g)×kg)

Control

Gefitinib 100

Gefitinib 200

n = 8

n = 7

n = 7

Blood

0.088 ± 0.009

0.080 ± 0.017

0.091 ± 0.012

Tumor

0.589 ± 0.112

0.393 ± 0.093*

0.360 ± 0.059*

Muscle

0.093 ± 0.008

0.088 ± 0.013

0.094 ± 0.008

Heart

0.094 ± 0.012

0.085 ± 0.012

0.092 ± 0.008

Brown fat

0.082 ± 0.010

0.076 ± 0.006

0.083 ± 0.009

Lung

0.091 ± 0.012

0.085 ± 0.011

0.094 ± 0.007

Brain

0.016 ± 0.001

0.015 ± 0.001

0.015 ± 0.001

Spleen

0.115 ± 0.026

0.113 ± 0.025

0.122 ± 0.033

Liver

0.103 ± 0.014

0.100 ± 0.017

0.105 ± 0.012

Kidney

0.147 ± 0.016

0.132 ± 0.020

0.138 ± 0.014

Skin

0.089 ± 0.019

0.094 ± 0.009

0.092 ± 0.010

Tumor/muscle ratio

6.3 ± 1.3

4.6 ± 1.4*

3.8 ± 0.6*

  1. *p < 0.01 vs. Control.